Valve size was an independent predictor for SVD. Long-term evaluation beyond 5 years after TAVI with a self-expanding bioprosthesis demonstrated low rates of cardiovascular mortality and structural valve deterioration. At multivariate analysis, the factor that emerged as an independent predictor for future SVD, was smaller bioprosthetic valve size (HR 0.58, 95% CI 0.41 to 0.82, p = 0.002). Actual analysis of the 8-year cumulative incidence of function of moderate SVD was 5.9% (2.5% to 16.2%). Five patients with SVD died during follow-up. Concerning SVD, 16 patients (6% of the total population) had moderate SVD (91% had an increase in mean gradient), with no severe SVD cases. Regarding valve performance, 5% of patients had early BVF and 1% had late BVF. At 1, 5, and 8 years, estimated survival rates were 89.0%, 61.1%, and 56.0%, respectively, while cardiovascular mortality was 8% at the end of follow-up. The median follow-up duration was 5 years (interquartile range: 2.9 to 6 longest: 8 years). The study prospectively evaluated 273 patients (80.61 ± 7.00 years old, 47% females) who underwent TAVI with CoreValve/Evolut-R (Medtronic Inc.). Primary end points were all-cause and cardiovascular mortality, structural valve deterioration (SVD) and bioprosthetic valve failure (BVF), based on the VARC-2 criteria and consensus statement by ESC/EAPCI. Consecutive patients scheduled for TAVI were included in the analysis. We sought to determine the long-term clinical outcomes and performance of a self-expanding bioprosthesis beyond 5 years. Transcatheter aortic valve implantation (TAVI) is an established method for treating patients with aortic valve stenosis.

Really long-term clinical outcomes and valve performance are reassuring in patients undergoing TAVI with the first and second generation self-expanding bioprosthesis.Įxtensive follow-up of low and medium surgical risk patients undergoing TAVI with the newer generation of transcatheter bioprostheses is needed. Long-term data for patients undergoing TAVI with the first generation self-expanding bioprosthesis are consistent with low mortality rates and satisfying valve performance.

Cumulative incidence in xlstat